{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:46:37Z","timestamp":1792889197005,"version":"4.5.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:p>Background: Huntington\u2019s disease (HD) is an autosomal dominant, neurological disease caused by an expanded CAG repeat near the N-terminus of the huntingtin (HTT) gene. A leading theory concerning the etiology of HD is that both onset and progression are driven by cumulative exposure to the effects of mutant (or CAG expanded) huntingtin (mHTT). The CAG-Age-Product (CAP) score (i.e., the product of excess CAG length and age) is a commonly used measure of this cumulative exposure. CAP score has been widely used as a predictor of a variety of disease state variables in HD. The utility of the CAP score has been somewhat diminished, however, by a lack of agreement on its precise definition. The most commonly used forms of the CAP score are highly correlated so that, for purposes of prediction, it makes little difference which is used. However, reported values of CAP scores, based on commonly used definitions, differ substantially in magnitude when applied to the same data. This complicates the process of inter-study comparison. Objective: In this paper, we propose a standardized definition for the CAP score which will resolve this difficulty. Our standardization is chosen so that CAP\u200a=\u200a100 at the expected age of diagnosis. Methods: Statistical methods include novel survival analysis methodology applied to the 13 disease landmarks taken from the Enroll-HD database (PDS 5) and comparisons with the existing, gold standard, onset model. Results: Useful by-products of our work include up-to-date, age-at-onset (AO) results and a refined AO model suitable for use in other contexts, a discussion of several useful properties of the CAP score that have not previously been noted in the literature and the introduction of the concept of a toxicity onset model. Conclusion: We suggest that taking L\u200a=\u200a30 and K\u200a=\u200a6.49 provides a useful standardization of the CAP score, suitable for use in the routine modeling of clinical data in HD.<\/jats:p>","DOI":"10.3233\/jhd-210475","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T12:14:05Z","timestamp":1650370445000},"page":"153-171","source":"Crossref","is-referenced-by-count":77,"title":["Standardizing the CAP Score in Huntington\u2019s Disease by Predicting Age-at-Onset"],"prefix":"10.1177","volume":"11","author":[{"given":"John H.","family":"Warner","sequence":"first","affiliation":[{"name":"CHDI Management\/CHDI Foundation, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Long","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry, Biostatistics, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Mills","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry, Biostatistics, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Langbehn","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry, Biostatistics, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ware","sequence":"additional","affiliation":[{"name":"CHDI Management\/CHDI Foundation, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Mohan","sequence":"additional","affiliation":[{"name":"CHDI Management\/CHDI Foundation, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"CHDI Management\/CHDI Foundation, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-210475_ref1","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JHD-210475_ref2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/B978-0-12-381328-2.00015-8","article-title":"Pathogenic mechanisms in Huntington\u2019s disease","volume":"98","author":"Jones","year":"2011","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"10.3233\/JHD-210475_ref3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell."},{"issue":"11","key":"10.3233\/JHD-210475_ref4","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1172\/JCI83185","article-title":"Targeting CAGrepeat RNAs reduces Huntington\u2019s disease phenotype independently ofhuntingtin levels","volume":"126","author":"Ru\u00e9","year":"2016","journal-title":"J Clin Invest."},{"issue":"8","key":"10.3233\/JHD-210475_ref5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/psp4.12097","article-title":"Modeling variability in the progression of Huntington\u2019s disease a novel modeling approach applied to structural imaging markers from TRACK-HD","volume":"5","author":"Warner","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"10.3233\/JHD-210475_ref6","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1002\/hbm.23713","article-title":"Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington\u2019s disease","volume":"38","author":"Wu","year":"2017","journal-title":"Hum Brain Ma"},{"issue":"1","key":"10.3233\/JHD-210475_ref7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pscychresns.2005.05.011","article-title":"Regional white matter change in pre-symptomatic Huntington\u2019s disease: a diffusion tensor imaging study","volume":"140","author":"Reading","year":"2005","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.3233\/JHD-210475_ref8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/mds.27963","article-title":"PET molecular imaging of phosphodiesterase 10A: an early biomarker of Huntington\u2019s disease progression","volume":"35","author":"Fazio","year":"2020","journal-title":"Mov Disord"},{"issue":"4","key":"10.3233\/JHD-210475_ref9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.3233\/JHD-210475_ref10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.3233\/JHD-210475_ref11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajmg.b.31232","article-title":"Indexing disease progression at study entry with individuals at-risk for Huntington disease","volume":"156b","author":"Zhang","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.3233\/JHD-210475_ref12","unstructured":"Mohan A , Sun Z , Ghosh S , Li Y , Cheng Y , Hu J , et al. A unified staging system for prodromal and manifest Huntington\u2019s disease [abstract]. Mov Disord. 2019;34(suppl 2)."},{"key":"10.3233\/JHD-210475_ref13","unstructured":"Wells R , Ashizawa T . Genetic instabilities and neurological diseases. Oxford: Elsevier 2006."},{"key":"10.3233\/JHD-210475_ref14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","article-title":"Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD Study","volume":"6","author":"Paulsen","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"10.3233\/JHD-210475_ref15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1474-4422(14)70238-8","article-title":"Prediction of manifest Huntington\u2019s disease with clinical and imaging measures: a prospective observational study","volume":"13","author":"Paulsen","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.3233\/JHD-210475_ref16","first-page":"689","article-title":", Vonsattel JP, MacDonald ME, Gusella JF, Myers RH","volume":"41","author":"Penney","year":"1997","journal-title":"CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Ann Neurol"},{"issue":"7","key":"10.3233\/JHD-210475_ref17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.3233\/JHD-210475_ref18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archneur.63.6.883","article-title":"Preparing for preventive clinical trials: the Predict-HD study","volume":"63","author":"Paulsen","year":"2006","journal-title":"Arch Neurol"},{"issue":"4","key":"10.3233\/JHD-210475_ref19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin Genet"},{"issue":"2","key":"10.3233\/JHD-210475_ref20","first-page":"212","article-title":"Data analytics from Enroll-HD, aglobal clinical research platform for Huntington\u2019s disease","volume":"4","author":"Landwehrmeyer","year":"2017","journal-title":"MovDisord Clin Pract."},{"key":"10.3233\/JHD-210475_ref22","unstructured":"Kalbfleisch D , Prentice R . The statistical analysis of failure time data. New York: John Wiley & Sons, Inc.; 2011."},{"issue":"10","key":"10.3233\/JHD-210475_ref25","first-page":"28","article-title":"Package \u2018survival\u2019","volume":"128","author":"Therneau","year":"2015","journal-title":"R Top Doc"},{"issue":"345","key":"10.3233\/JHD-210475_ref26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/01621459.1974.10480146","article-title":"Nonparametric estimation of a survivorship function with doubly censored data","volume":"69","author":"Turnbull","year":"1974","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.3233\/JHD-210475_ref29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches","volume":"153b","author":"Langbehn","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.3233\/JHD-210475_ref30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-12-801893-4.00004-3","article-title":"Statistical modeling of Huntington disease onset","volume":"144","author":"Garcia","year":"2017","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"10.3233\/JHD-210475_ref31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/mds.26838","article-title":"Validation of a prognostic index for Huntington\u2019s disease","volume":"32","author":"Long","year":"2017","journal-title":"Mov Disord"},{"issue":"11","key":"10.3233\/JHD-210475_ref32","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2019.2368","article-title":"Association of CAG repeats with long-term progression in Huntington disease","volume":"76","author":"Langbehn","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.3233\/JHD-210475_ref33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajhg.2021.12.002","article-title":"Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease","volume":"109","author":"Langbehn","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.3233\/JHD-210475_ref34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajhg.2015.12.018","article-title":"The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease","volume":"98","author":"Keum","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.3233\/JHD-210475_ref35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/JHD-200395","article-title":"Biological aging and the cellular pathogenesis of Huntington\u2019s disease","volume":"9","author":"Machiela","year":"2020","journal-title":"J Huntingtons Dis"},{"issue":"6","key":"10.3233\/JHD-210475_ref36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/arclin\/acaa026","article-title":"Cognitive and motor norms for Huntington\u2019s Disease","volume":"35","author":"Mills","year":"2020","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"10.3233\/JHD-210475_ref37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/JHD-200421","article-title":"Drugging DNA damage repair pathways for trinucleotide repeat expansion diseases","volume":"10","author":"Benn","year":"2021","journal-title":"J Huntingtons Dis"},{"issue":"11","key":"10.3233\/JHD-210475_ref38","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1093\/hmg\/dds059","article-title":"High levels of somatic DNA diversity at the myotonic dystrophy type 1 locus are driven by ultra-frequent expansion and contraction mutations","volume":"21","author":"Higham","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.3233\/JHD-210475_ref39","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1371\/journal.pcbi.0030235","article-title":"A universal mechanism ties genotype to phenotype in trinucleotide diseases","volume":"3","author":"Kaplan","year":"2007","journal-title":"PLoS Comp Biol"},{"key":"10.3233\/JHD-210475_ref40","unstructured":"Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell. 2015;162(3):516\u201326."},{"issue":"R2","key":"10.3233\/JHD-210475_ref41","doi-asserted-by":"crossref","first-page":"R254","DOI":"10.1093\/hmg\/ddab170","article-title":"Huntington\u2019s disease: nearly four decades of human molecular genetics","volume":"30","author":"Gusella","year":"2021","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.3233\/JHD-210475_ref42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/biomet\/84.2.339","article-title":"A consistent estimator for the distribution of quality adjusted survival time","volume":"84","author":"Zhao","year":"1997","journal-title":"Biometrika"},{"issue":"4","key":"10.3233\/JHD-210475_ref43","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.0006-341X.1999.01101.x","article-title":"Efficient estimation of the distribution of quality-adjusted survival time","volume":"55","author":"Zhao","year":"1999","journal-title":"Biometrics"},{"issue":"22","key":"10.3233\/JHD-210475_ref44","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1212\/WNL.0b013e318294b304","article-title":"Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS","volume":"80","author":"Killoran","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JHD-210475_ref45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/cge.12324","article-title":"Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results","volume":"85","author":"Semaka","year":"2014","journal-title":"Clin Genet"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-210475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:06Z","timestamp":1777452966000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-210475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":40,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-210475","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]}}}